Basic Biopharmaceutics Workshop
Develop your knowledge on core theoretical principles and the application of biopharmaceutics to aid progression of oral drug development projects.
The APS are pleased to announce a unique opportunity of a one-day workshop focused on oral biopharmaceutics and the science of oral absorptiondelivered by a mix of industrial and academic experts in oral biopharmaceutics with many years of experience.
Topics covered include
- Basic fundamental principles of oral biopharmaceutics
- Impact of small molecule physicochemical properties
- Biopharmaceutical properties on oral bioavailability
- Gastrointestinal physiology
- Basic pharmacokinetics principles
- Biopharmaceutical classification scheme
- Biomodelling tools to predict oral absorption
- Regulatory biopharmaceutics
Speakers are from large pharma, biotechnology companies, contract research organisations, University of Birmingham, Univerisity of Strathclyde, Uniersity of Huddersfield and the University of Bath.
There will be many opportunities to network and talk with the speakers. A compound example will be integrated within all presentations and used to build an example of a biopharmaceutics risk assessment. This will be discussed in a round table format and will allow attendees the opportunity to question how biopharmaceutics data can be used to define key risks for oral product design and development.
Please click here to register
This meeting is aimed at students, academics, industrial and regulatory scientists working in the areas of formulation design, regulatory CMC and analytical development and will provide a comprehensive introduction to biopharmaceutics and the science of oral absorption. Presentations from experienced academic and industrial scientists will provide delegates with a broad understanding of the key scientific and technical issues relevant to oral biopharmaceutics. Biopharmaceutics is a multi-disciplinary subject area and talks will span a diverse range of topics including physicochemical profiling, gastrointestinal physiology, biomodelling and regulatory concepts in biopharmaceutics.
|0830||Registration and coffee|
|0920||Welcome, Introductions and Biopharmaceutics Basics
Mark McAllister, Pfizer
|0940||Physicochemical Properties for Biopharmaceutics
Speaker: Ibrahim Khadra, University of Strathclyde
|1020||Biopharmaceutical Properties (e.g Permeability)
Speaker: Chris Roe, Quotient
|1100||Tea & coffee|
Speaker: Nikoletta Fotaki, University of Bath
Speaker: Mark McAllister, Pfizer
|1340||Basic Pharmacokinetics Principles
Speaker: Hamid Merchant, University of Huddersfield
|1420||Biopharmaceutical Classification Scheme (BCS)
Speaker: Hannah Batchelor, University of Birmingham
|1500||Tea & coffee|
|1520||Biomodels and simulations
Speaker: Alison Wilby, Quotient
Speaker: Paul Dickinson, SEDA
|1640||Team based review of material covered|
|Mark McAllister||Mark is the Drug Delivery Group Leader at Pfizer, UK.
He was co-lead for the Orbito network, a project that aimed to enhance understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients
|Ibrahim Khadra||Ibrahim is a Lecturer at Strathclyde University and has extensive experience in the development of oral dosage forms, analytical methods, pharmacokinetics and regulatory affairs within the pharmaceutical industry and academia.|
|Chris Roe||Chris is a Senior Research Fellow at Quotient Sciences who has previously worked at AstraZeneca. He has experience in early pharmaceutical product development.|
|Nikoletta Fotaki||Nikoletta is a Reader at the University of Bath. Her research is focussed on the development of in vitro screening tools and associated softwares for predicting oral absorption, the assessment of the impact of changes in drug substance properties and changes in the formulation process on bioavailability , animal models for predicting absorption, and in vitro-in vivo correlations/ in vitro-in vivo relations.|
|Hannah Batchelor||Hannah is a Senior Lecturer at the University of Birmingham. Her research focuses on the design and manipulation of medicines to create age appropriate drug formulations to maximise clinical efficacy in paediatric patients. This encompasses pharmaceutical science as well as clinical evaluations of medicines administered to children.|
|Alison Wilby||Alison is a Modelling and Simulation Scientist at Quotient, UK. She is a PhD-qualified DMPK specialist with over 10 years experience in the pharmaceutical industry.|
|Paul Dickinson||Paul is Director of Product Performance at Seda, UK. Paul has held several senior science leadership roles in Academia and Large Pharma. These roles focused on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines.|
|Hamid Merchant||Hamid is a Subject Lead at the Department of Pharmacy, University of Huddersfield. He has a formulation sciences background with extensive experience both from industry and academia. He has a particular interest in drug delivery research at the interface of gastroenterology. His clinical knowledge and expertise in pharmaceutics helps students to understand the clinical and therapeutic principles underpinning the science of dosage form design.|